Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Apr 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a new treatment called cell therapy, specifically CAR T-cell therapy, on patients with a condition known as autoimmune hemolytic anemia (AIHA). While this innovative treatment can help manage AIHA, researchers are also looking at how it affects brain function and psychological well-being. They want to understand if the therapy causes any changes in thinking or behavior, which could be important for keeping patients safe and helping them live better lives.

To participate in this trial, you need to be between 18 and 65 years old and have a diagnosis of AIHA. You will receive the CAR T-cell therapy as part of the study. However, if you have a history of serious mental health issues or severe brain diseases, you may not be eligible to join. Throughout the trial, participants will undergo assessments to monitor both their physical and mental health, helping to identify any issues early on. The goal is to find ways to make this treatment safer and more effective for patients, ultimately improving their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of AIHA
• • Subjects will receive cell therapy such as CAR T-cell therapy
• • Male or female, aged 18-65 years
• • Willing and able to comply with the requirements for this study and written informed consent
• Exclusion Criteria:
• • History of psychiatric illness
• • History of severe brain disease
• • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study